- Home
- FOR vs SYRE Comparison
FOR vs SYRE Comparison
Compare FOR & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOR
- SYRE
- Stock Information
- Founded
- FOR 2005
- SYRE 2013
- Country
- FOR United States
- SYRE United States
- Employees
- FOR N/A
- SYRE N/A
- Industry
- FOR Real Estate
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- FOR Finance
- SYRE Health Care
- Exchange
- FOR Nasdaq
- SYRE Nasdaq
- Market Cap
- FOR 1.0B
- SYRE 841.4M
- IPO Year
- FOR 2007
- SYRE 2016
- Fundamental
- Price
- FOR $21.73
- SYRE $15.76
- Analyst Decision
- FOR Strong Buy
- SYRE Buy
- Analyst Count
- FOR 3
- SYRE 6
- Target Price
- FOR $30.33
- SYRE $55.00
- AVG Volume (30 Days)
- FOR 150.8K
- SYRE 657.5K
- Earning Date
- FOR 07-22-2025
- SYRE 08-06-2025
- Dividend Yield
- FOR N/A
- SYRE N/A
- EPS Growth
- FOR N/A
- SYRE N/A
- EPS
- FOR 3.29
- SYRE N/A
- Revenue
- FOR $1,471,000,000.00
- SYRE N/A
- Revenue This Year
- FOR $3.95
- SYRE N/A
- Revenue Next Year
- FOR $8.86
- SYRE N/A
- P/E Ratio
- FOR $6.61
- SYRE N/A
- Revenue Growth
- FOR N/A
- SYRE N/A
- 52 Week Low
- FOR $18.00
- SYRE $10.91
- 52 Week High
- FOR $37.21
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- FOR 66.84
- SYRE 50.55
- Support Level
- FOR $19.88
- SYRE $14.00
- Resistance Level
- FOR $21.92
- SYRE $16.61
- Average True Range (ATR)
- FOR 0.67
- SYRE 1.34
- MACD
- FOR 0.21
- SYRE -0.10
- Stochastic Oscillator
- FOR 92.86
- SYRE 44.85
About FOR Forestar Group Inc
Forestar Group Inc is a residential lot development company with operations across the United States. The core business segment for the company is real estate which generates all of it's revenues. The firm fundamentally acquires entitled real estate and develops it into finished residential lots for sale to homebuilders with a strategic focus on asset turns and efficiency. Single-family residential communities account for the majority of their real estate projects. The company utilizes a lower-risk business model mainly by investing in short duration, phased development projects.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.